Difference between revisions of "Ramucirumab (Cyramza)"
Jump to navigation
Jump to search
m |
m |
||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 4/21/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm | + | ===[[Colon cancer]]=== |
| − | * 11/5/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm421930.htm | + | * 4/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm Approved] in combination with [[Colon_cancer#FOLFIRI_.26_Ramucirumab|FOLFIRI]], for the treatment of [[Colon cancer | metastatic colorectal cancer]] with disease progression on or after prior therapy with [[Bevacizumab (Avastin)|bevacizumab]], [[Oxaliplatin (Eloxatin)|oxaliplatin]], and a fluoropyrimidine. ''(New disease approval)'' |
| − | * 12/12/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm | + | |
| − | + | ===[[Gastric cancer]]=== | |
| + | * 4/21/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm394260.htm Initial approval] for the treatment of patients with advanced or metastatic, [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]] with disease progression on or after prior treatment with fluoropyrimidine- or [[:Category:Platinum_agents|platinum-]] containing chemotherapy. | ||
| + | * 11/5/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm421930.htm Approval and indication expanded] for use in combination with [[Paclitaxel (Taxol) | paclitaxel]] for the treatment of patients with advanced [[Gastric cancer | gastric or gastroesophageal junction (GEJ) adenocarcinoma]]. ''(Requirement for prior lines of treatment removed)'' | ||
| + | |||
| + | ===[[Hepatocellular carcinoma]]=== | ||
| + | * 5/10/2019: Approved as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of at least 400 ng/mL and have been previously treated with sorafenib. ''(New disease approval)'' | ||
| + | |||
| + | ===[[Non-small cell lung cancer]]=== | ||
| + | * 12/12/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm Approved] for use in combination with [[Docetaxel (Taxotere)|docetaxel]] for the treatment of patients with [[Non-small cell lung cancer | metastatic non-small cell lung cancer (NSCLC)]] with disease progression on or after [[:Category:Platinum_agents|platinum-based]] chemotherapy. ''(New disease approval)'' | ||
==Also known as== | ==Also known as== | ||
Revision as of 01:03, 11 May 2019
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ramucirumab (Cyramza) patient drug information (Chemocare)[4]
- Ramucirumab (Cyramza) package insert[1]
- Ramucirumab (Cyramza) patient drug information (UpToDate)[5]
History of changes in FDA indication
Colon cancer
- 4/24/2015: Approved in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. (New disease approval)
Gastric cancer
- 4/21/2014: Initial approval for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum- containing chemotherapy.
- 11/5/2014: Approval and indication expanded for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (Requirement for prior lines of treatment removed)
Hepatocellular carcinoma
- 5/10/2019: Approved as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of at least 400 ng/mL and have been previously treated with sorafenib. (New disease approval)
Non-small cell lung cancer
- 12/12/2014: Approved for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. (New disease approval)
Also known as
- Code names: IMC-1121B, LY3009806
- Brand name: Cyramza